Study Details: Examine the efficacy of toceranib phosphate (Palladia) as a primary and/or adjuvant agent in the treatment of canine nasal carcinoma.
Tumor: Nasal Carcinoma
Purpose of study: All tumors must develop new blood vessels in order to grow. Palladia is a tyrosine kinase inhibitor that inhibits the development of new blood vessels by targeting receptors called vascular endothelial growth factor receptors. These receptors have been documented to occur in canine nasal tumors and early reports indicate that Palladia has primary activity in these tumors. Palladia has also been shown to sensitize tumor tissues to the effects of radiation therapy. Because of these findings, clinical investigation of Palladia as therapy for nasal carcinomas, alone or in combination with radiation therapy is needed to know if we can increase our efficacy in controlling these tumors in comparison to radiation therapy alone. We also need to monitor for any side effects.
- For more information: contact Annette Smith, D.V.M., Oncology Service Director, Department of Clinical Sciences. 334-844-4690